BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bomanji, J B
Right arrow Articles by Ell, P J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bomanji, J B
Right arrow Articles by Ell, P J
British Journal of Radiology 74 (2001),266-269 © 2001 The British Institute of Radiology

Case report

Functional imaging as an aid to decision-making in metastatic paraganglioma

J B Bomanji, MBBS, MSc, PhD 1 S W Hyder, MB 1 M N Gaze, MD, FRCR 2 S Gacinovic, MD, MSc 1 D C Costa, MD, PhD, FRCR 1 C Coulter, FRCR 2 and P J Ell, FRCP, FRCR 1

1 The Institute of Nuclear Medicine 2 Meyerstein Institute of Oncology, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK

Malignant paraganglioma is a rare and slow growing tumour of neuroendocrine origin. At the time of diagnosis, the tumour is usually widespread, with limited therapeutic options. A variety of functional imaging studies are available for staging the disease, guiding therapy and monitoring treatment response. These include 123I-MIBG or 131I-MIBG, 111In-pentetreotide or 111In-lanreotide (somatostatin analogues), and 18F-FDG positron emission tomography. Various radionuclides, including 131I and 90Y, can be targeted to the tumour using MIBG or pentetreotide. Such targeted radionuclide therapy may provide valuable long-term palliation in such patients. We present two cases with metastatic paragangliomas who had widespread soft tissue and bone metastases. One patient was treatment naive and the second had received previous chemotherapy. The functional imaging work-up performed and the targeted radionuclide therapies considered in these patients are described. Both patients were treated with 131I-MIBG. Partial tumour response and complete symptomatic and hormonal response was achieved in one patient; in the second patient there was no change.




This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
K Zaplatnikov, C Menzel, N Dobert, N Hamscho, W T Kranert, M Gotthard, T M Behr, and F Grunwald
Drug interference with MIBG uptake in a patient with metastatic paraganglioma
Br. J. Radiol., June 1, 2004; 77(918): 525 - 527.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2001 by the British Institute of Radiology.